Dr. Keystone, et al, reply

REFERENCES

1. 1.↵
   1. Abeles AM

   . Five-year data from the REFLEX Study: a different interpretation. J Rheumatol 2013;40:732.

   OpenUrlFREE Full Text
2. 2.↵
   1. Keystone EC,
   2. Cohen SB,
   3. Emery P,
   4. Kremer JM,
   5. Dougados M,
   6. Loveless JE,
   7. et al.

   Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012;39:2238–346.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Cohen SB,
   2. Keystone E,
   3. Genovese MC,
   4. Emery P,
   5. Peterfy C,
   6. Tak PP,
   7. et al.

   Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis 2010;69:1158–61.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Bombardieri S,
   2. Ruiz AA,
   3. Fardellone P,
   4. Geusens P,
   5. McKenna F,
   6. Unnebrink K,
   7. et al; and
   8. Research in Active Rheumatoid Arthritis (ReAct) Study Group

   . Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology 2007;46:1191–9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Emery P,
   2. Keystone E,
   3. Tony HP,
   4. Cantagrel A,
   5. van Vollenhoven R,
   6. Sanchez A,
   7. et al.

   IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Schiff M,
   2. Keiserman M,
   3. Codding C,
   4. Songcharoen S,
   5. Berman A,
   6. Nayiager S,
   7. et al.

   Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis 2011;70:2003–7.

   OpenUrlAbstract/FREE Full Text